4203 articles
The Therapeutics Products Act (TPA) 2023 has been repealed, despite being hailed by now-former health minister Dr Ayesha Verrall as the most significant change to the regulation of medicines, medical devices and natural health products in New Zealand in nearly 40 years.
Danish brand Monoqool has created its first AI-generated design, Wild Thing. Generated via text prompts, the AI design was refined through countless alterations, said the company. The technology offered lots of inspiration for how a unique pair of glasses could look, it said.
CDR-Life is recruiting for phase 2 clinical trials of its novel antibody fragment-based therapy for geographic atrophy (GA), following favourable phase 1 safety results.
A groundbreaking, experimental stem cell treatment for blinding cornea injuries resulted in a 92% success rate at 18 months.
Blackfin’s latest campaign introduces a collection combining innovation and style through the brand’s minimalistic creative vision and cutting-edge technologies. With new designs available in the Blackfin One, Areo Loop, Pacific and Atlantic series, the Pacific Mendocino featured here stands out for
An Australian research team has developed a large language model (LLM) designed to speed up scientific discovery in molecular property prediction. Lead co-author, PhD candidate Yizhen Zheng, from Mo
An international team including New Zealand researchers found measures of retinal health captured the risk of Alzheimer's disease and related dementias (ADRD) across several domains of known risk fact
The Ministry of Health (MoH) is reviewing the regulation of the New Zealand health workforce and is asking for submissions.
A Moorfields-led team improved the visual acuity (VA) in children with retinal dystrophy caused by a genetic deficiency of AIPL1, using a viral vector to deliver healthy copies of the gene to their re
SpliceBio, a clinical-stage genetic medicine company pioneering protein splicing, has dosed the first patient in the phase 1/2 ASTRA study of SB-007, a dual adeno-associated viral (AAV) vector for the
Luxa Biotechnology announced trial results showing substantial improvements in best corrected visual acuity (BCVA) for patients receiving its novel adult retinal pigment epithelial stem cell therapy (
Neurotech Pharmaceuticals announced its Encelto (revakinagene taroretcel-lwey) implant has become the first US Food and Drug Administration (FDA)-approved therapy to slow macular telangiectasia (MacTe
